Skip to main content
. 2018 Apr 19;2:PO.17.00267. doi: 10.1200/PO.17.00267

Fig 1.

Fig 1.

Genomic landscape of pancreatic neuroendocrine tumors, including the first sequenced sample for each patient (n = 80), as identified by the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets. LOH, loss of heterozygosity; Mb, megabyte; mTOR, mammalian target of rapamycin.